Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Karyopharm Therapeut (KPTI)

Karyopharm Therapeut (KPTI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Do Options Traders Know Something About Karyopharm (KPTI) Stock We Don't?

Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

KPTI : 15.38 (+6.95%)
U.S. Food and Drug Administration Accepts Karyopharm's Supplemental New Drug Application for XPOVIO(R) (Selinexor) as a Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing its supplemental New Drug...

KPTI : 15.38 (+6.95%)
Karyopharm to Participate at 9th Annual SVB Leerink Global Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will participate in a fireside chat at the...

KPTI : 15.38 (+6.95%)
Karyopharm Thera Falls 2.26% on Heavy Volume: Watch For Potential Rebound

Karyopharm Thera (NASDAQ:KPTI) traded in a range yesterday that spanned from a low of $16.05 to a high of $17.00. Yesterday, the shares fell 2.3%, which took the trading range below the 3-day low of...

KPTI : 15.38 (+6.95%)
Karyopharm Therapeutics: 4Q Earnings Snapshot

NEWTON, Mass. (AP) _ Karyopharm Therapeutics Inc. (KPTI) on Thursday reported a loss of $48.6 million in its fourth quarter.

KPTI : 15.38 (+6.95%)
Karyopharm Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress

-- XPOVIO Net Product Sales of $17.7 Million for Fourth Quarter and $30.5 Million for Full Year 2019 --

KPTI : 15.38 (+6.95%)
What's in Store for AstraZeneca (AZN) This Earnings Season?

AstraZeneca's (AZN) fourth-quarter results are expected to reflect the impact of new drug sales.

AZN : 45.07 (-5.26%)
MRK : 78.08 (-2.33%)
NKTR : 20.53 (-4.11%)
KPTI : 15.38 (+6.95%)
Karyopharm and Promedico, a Member of the Neopharm Group, Enter into an Exclusive Distribution Agreement to Commercialize XPOVIO(R) (Selinexor) in Israel

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, and Promedico, a member of the Neopharm Group, today announced their entry into an exclusive distribution agreement...

KPTI : 15.38 (+6.95%)
What's in Store for Acorda (ACOR) This Earnings Season?

During Acorda's (ACOR) Q4 earnings call, investor focus will be on the sales uptake of its newly-launched Parkinson's disease drug Inbrija.

ACOR : 1.33 (+0.76%)
MYL : 18.68 (-4.40%)
KPTI : 15.38 (+6.95%)
VCEL : 15.01 (-0.20%)
What's in Store for Ironwood (IRWD) This Earnings Season?

Ironwood Pharmaceuticals' (IRWD) Linzess is likely to have driven total revenues in the fourth quarter.

IRWD : 11.90 (+7.50%)
AZN : 45.07 (-5.26%)
AGN : 189.52 (-1.90%)
KPTI : 15.38 (+6.95%)
Karyopharm to Report Fourth Quarter and Full Year 2019 Financial Results on February 13, 2020

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that it will report fourth quarter and full year 2019 financial results on Thursday, February 13,...

KPTI : 15.38 (+6.95%)
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase...

KPTI : 15.38 (+6.95%)
Options Traders Expect Huge Moves in Karyopharm (KPTI) Stock

Investors need to pay close attention to Karyopharm (KPTI) stock based on the movements in the options market lately.

KPTI : 15.38 (+6.95%)
BioLineRx's Pancreatic Cancer Drug Gets Orphan Drug Tag in EU

The European Commission bestows an orphan drug status on BioLineRx's (BLRX) lead candidate Motixafortide, currently being evaluated with Merck's Keytruda to treat pancreatic cancer. Stock up.

MRK : 78.08 (-2.33%)
RHHBY : 40.7850 (-3.24%)
KPTI : 15.38 (+6.95%)
BLRX : 1.89 (+3.28%)
Aclaris' MK2 Inhibitor Shows Encouraging Data in Phase I

Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.

AGN : 189.52 (-1.90%)
RIGL : 2.04 (-5.99%)
ACRS : 1.14 (-7.32%)
KPTI : 15.38 (+6.95%)
Karyopharm Announces Preliminary Unaudited Fourth Quarter and Full Year 2019 Product Sales for XPOVIO(R) (selinexor) and Provides Commercial Update

-- XPOVIO Unaudited Net Product Sales of between $17 and $18 Million for Fourth Quarter 2019 and between $30 and $31 Million for the Full Year 2019 --

KPTI : 15.38 (+6.95%)
Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

Zacks.com featured highlights include: Cassava Sciences, Rubicon Project, Talos Energy, Teekay Tankers and Karyopharm Therapeutics

TNK : 14.70 (+16.11%)
RUBI : 10.67 (-3.35%)
KPTI : 15.38 (+6.95%)
SAVA : 5.94 (-7.62%)
TALO : 13.83 (-9.19%)
5 Stocks With Recent Price Strength for Spectacular Returns

Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.

TNK : 14.70 (+16.11%)
RUBI : 10.67 (-3.35%)
KPTI : 15.38 (+6.95%)
SAVA : 5.94 (-7.62%)
TALO : 13.83 (-9.19%)
Karyopharm to Present at the 38th Annual J.P. Morgan Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), an oncology-focused pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 38th Annual J.P. Morgan...

JPM : 121.37 (-4.16%)
KPTI : 15.38 (+6.95%)
Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), an oncology-focused pharmaceutical company, today announced that the Compensation Committee of Karyopharm's Board of Directors granted stock options to purchase...

KPTI : 15.38 (+6.95%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS -3.69 , SEDG -6.46 , THC -1.06 , TER -3.02 , LITE -2.73
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar